Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer

Overview

Journal Curr Genomics

Publisher Bentham Science Publishers

Date 2022 Mar 11

PMID 35273457

Authors

Sukanya Panja

Sarra Rahem

Cassandra J Chu

Antonina Mitrofanova

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, the availability of high throughput technologies, establishment of large molecular patient data repositories, and advancement in computing power and storage have allowed elucidation of complex mechanisms implicated in therapeutic response in cancer patients. The breadth and depth of such data, alongside experimental noise and missing values, requires a sophisticated human-machine interaction that would allow effective learning from complex data and accurate forecasting of future outcomes, ideally embedded in the core of machine learning design.

Objective: In this review, we will discuss machine learning techniques utilized for modeling of treatment response in cancer, including Random Forests, support vector machines, neural networks, and linear and logistic regression. We will overview their mathematical foundations and discuss their limitations and alternative approaches in light of their application to therapeutic response modeling in cancer.

Conclusion: We hypothesize that the increase in the number of patient profiles and potential temporal monitoring of patient data will define even more complex techniques, such as deep learning and causal analysis, as central players in therapeutic response modeling.

Citing Articles

Role of hippo pathway and cuproptosis-related genes in immune infiltration and prognosis of skin cutaneous melanoma.

Lv H, Liu L, He Y, Yang K, Fu Y, Bao Y Front Pharmacol. 2024; 15:1344755.

PMID: 38515849 PMC: 10955143. DOI: 10.3389/fphar.2024.1344755.

The global patent landscape of artificial intelligence applications for cancer.

Braga L, Lopes R, Alves L, Mota F Nat Biotechnol. 2023; 41(12):1679-1687.

PMID: 38082076 DOI: 10.1038/s41587-023-02051-9.

The role of cuproptosis-related gene in the classification and prognosis of melanoma.

Liu J, Liu L, Li Z, Luo Y, Liang F Front Immunol. 2022; 13:986214.

PMID: 36341437 PMC: 9632664. DOI: 10.3389/fimmu.2022.986214.

Mate Analysis of Hepatocellular Carcinoma Immune Subtypes and Their Functional Effects Based on Fuzzy Logic and Evolutionary Algorithms.

Chen Q, Liu C, Huo Y Contrast Media Mol Imaging. 2022; 2022:5787981.

PMID: 35601568 PMC: 9098361. DOI: 10.1155/2022/5787981.

Machine Learning Accuracy and Big Data in Research on Disease and Health.

Stella F Curr Genomics. 2022; 22(4):237-238.

PMID: 35273455 PMC: 8822230. DOI: 10.2174/138920292204211203155613.

References

Polano M, Chierici M, Dal Bo M, Gentilini D, Di Cintio F, Baboci L . A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning. Cancers (Basel). 2019; 11(10). PMC: 6827166. DOI: 10.3390/cancers11101562. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Yu K, Chen B, Aran D, Charalel J, Yau C, Wolf D . Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat Commun. 2019; 10(1):3574. PMC: 6687785. DOI: 10.1038/s41467-019-11415-2. View

Horiguchi K, Toi M, Horiguchi S, Sugimoto M, Naito Y, Hayashi Y . Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J Med Dent Sci. 2010; 57(2):165-75. View

Sannachi L, Gangeh M, Tadayyon H, Gandhi S, Wright F, Slodkowska E . Breast Cancer Treatment Response Monitoring Using Quantitative Ultrasound and Texture Analysis: Comparative Analysis of Analytical Models. Transl Oncol. 2019; 12(10):1271-1281. PMC: 6639683. DOI: 10.1016/j.tranon.2019.06.004. View

Shen W, Chen S, Wu K, Lee P, Feng C, Hsieh T . Predicting pathological complete response in rectal cancer after chemoradiotherapy with a random forest using F-fluorodeoxyglucose positron emission tomography and computed tomography radiomics. Ann Transl Med. 2020; 8(5):207. PMC: 7154452. DOI: 10.21037/atm.2020.01.107. View

Land W, Margolis D, Gottlieb R, Krupinski E, Yang J . Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theory. BMC Genomics. 2010; 11 Suppl 3:S15. PMC: 2999345. DOI: 10.1186/1471-2164-11-S3-S15. View

Haasdonk B . Feature space interpretation of SVMs with indefinite kernels. IEEE Trans Pattern Anal Mach Intell. 2005; 27(4):482-492. DOI: 10.1109/TPAMI.2005.78. View

Nasief H, Zheng C, Schott D, Hall W, Tsai S, Erickson B . A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. NPJ Precis Oncol. 2019; 3:25. PMC: 6778189. DOI: 10.1038/s41698-019-0096-z. View

10.

Santoro G, Turvani G, Graziano M . New Logic-In-Memory Paradigms: An Architectural and Technological Perspective. Micromachines (Basel). 2019; 10(6). PMC: 6630546. DOI: 10.3390/mi10060368. View

11.

Tolles J, Meurer W . Logistic Regression: Relating Patient Characteristics to Outcomes. JAMA. 2016; 316(5):533-4. DOI: 10.1001/jama.2016.7653. View

12.

Rudin C . Stop Explaining Black Box Machine Learning Models for High Stakes Decisions and Use Interpretable Models Instead. Nat Mach Intell. 2022; 1(5):206-215. PMC: 9122117. DOI: 10.1038/s42256-019-0048-x. View

13.

Quigley D, Dang H, Zhao S, Lloyd P, Aggarwal R, Alumkal J . Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018; 174(3):758-769.e9. PMC: 6425931. DOI: 10.1016/j.cell.2018.06.039. View

14.

Mani S, Chen Y, Arlinghaus L, Li X, Chakravarthy A, Bhave S . Early prediction of the response of breast tumors to neoadjuvant chemotherapy using quantitative MRI and machine learning. AMIA Annu Symp Proc. 2011; 2011:868-77. PMC: 3243164. View

15.

Menden M, Iorio F, Garnett M, McDermott U, Benes C, Ballester P . Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One. 2013; 8(4):e61318. PMC: 3640019. DOI: 10.1371/journal.pone.0061318. View

16.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

17.

Bilsland A, Pugliese A, Liu Y, Revie J, Burns S, McCormick C . Identification of a Selective G1-Phase Benzimidazolone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks. Neoplasia. 2015; 17(9):704-715. PMC: 4611071. DOI: 10.1016/j.neo.2015.08.009. View

18.

Lind A, Anderson P . Predicting drug activity against cancer cells by random forest models based on minimal genomic information and chemical properties. PLoS One. 2019; 14(7):e0219774. PMC: 6622537. DOI: 10.1371/journal.pone.0219774. View

19.

Blackford A, Canto M, Klein A, Hruban R, Goggins M . Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Inst. 2020; 112(11):1162-1169. PMC: 7669234. DOI: 10.1093/jnci/djaa004. View

20.

Abajian A, Murali N, Savic L, Laage-Gaupp F, Nezami N, Duncan J . Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept. J Vasc Interv Radiol. 2018; 29(6):850-857.e1. PMC: 5970021. DOI: 10.1016/j.jvir.2018.01.769. View